Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Each tie as a share of each side’s annual revenue; the bigger share is the more dependent side.
| Partner | % of their revenue | % of ABBV revenue | Skew |
|---|---|---|---|
| DHCDiversified Healthcare Trust | 1.90% | 0.05% | 40× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In July 2024, we entered into a license agreement (the "AbbVie License Agreement") with AbbVie, pursuant to which we have been granted a license to research, develop and commercialize certain CFTR compounds.”
FILING10-K0001628280-26-012996cik 0002036042disclosed by SION
“Abbvie Inc. 197,976 3.0% 3,955 1.9% 2027”
$29M relationship40× more of DHC’s book than ABBV’s
basisDHC fy2025 · closed 2025-12 $1.5BABBV fy2025 · closed 2025-12 $61.2B
FILING10-K0001075415-25-000012cik 0001075415disclosed by DHC
“For example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix.”
FILING10-K0000914475-26-000007cik 0000914475disclosed by NBIX
“Our royalty revenue is generated through our Collaborative Development and License Agreement with AbbVie, under which we have discovered and out-licensed to AbbVie two protease inhibitor compounds that have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for HCV.”
FILING10-K0001193125-25-288121cik 0001177648disclosed by ENTA
“To date, we have generated our revenue through a Collaboration and Option Agreement, or the Collaboration Agreement, with AbbVie Global Enterprises Ltd., or AbbVie, which terminated in accordance with its terms in July 2025.”
FILING10-K0001193125-26-088172cik 0001472012disclosed by IMNM
“Under the European License agreement, AbbVie is obligated to pay us (i) certain commercial milestones totaling up to $42.5 million, (ii) royalties based on sales volume in Europe, beginning in the mid-single digits percent and escalating to the upper-teens percent, and (iii) on a country-by-country and product-by-product basis in the Expanded Territory, a royalty as a percentage of net sales of products containing linaclotide as an active ingredient in the upper-single digits for five years following the first commercial sale of a linaclotide product in a country, and in the low-double digits thereafter.”
FILING10-K0001104659-26-020489cik 0001446847disclosed by IRWD
“Under the terms of our Collaboration and License Agreement with AbbVie (the AbbVie Collaboration and License Agreement), we received an upfront payment of $370 million.”
FILING10-K0000950170-25-038770cik 0001590877disclosed by RGNX
“In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States.”
FILING10-K0001551152-26-000008cik 0001551152
“In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States.”
FILING10-K0001551152-26-000008cik 0001551152
“The Varseta-M payload is a topoisomerase-1 inhibitor licensed from AbbVie (formerly ImmunoGen), tailored to have anti-tumor activity against EpCAM-expressing cancer types.”
FILING10-K0001193125-26-107146cik 0001501989disclosed by CTMX
“In September 2019, we entered into an exclusive license agreement with AbbVie. Under the license agreement with AbbVie, or the AbbVie Agreement, we obtained an exclusive, worldwide license, with the right to sublicense to commercial pharmaceutical and biopharmaceutical companies (subject to AbbVie's prior consent or pre-authorization, except with respect to our affiliates), under certain patents and technical information of AbbVie, to make, have made, use, have used, sell, have sold, lease, have leased, import, have imported or otherwise transfer licensed products for all therapeutic, diagnostic and prophylactic uses in humans and animals, excluding uses in neuroscience and neurology.”
FILING10-K0001193125-26-073602cik 0001816736disclosed by IRON
“Research and development expenses include amounts owed to AbbVie on an ongoing basis under cost-sharing provisions in our collaboration agreement for linaclotide.”
FILING10-K0001104659-26-020489cik 0001446847disclosed by IRWD
“Included in cost of product sales are royalties owed to AbbVie on Revuforj sales as part of the Vitae License Agreement.”
FILING10-K0001193125-26-076536cik 0001395937disclosed by SNDX
“In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States.”
FILING10-K0001551152-26-000008cik 0001551152
“Our operations have been financed primarily through our collaboration with GSK, our previous collaboration with AbbVie, entered into in October 2017 and terminated in February 2025, the issuance and sale of convertible preferred stock and of common stock upon the completion of our initial public offering (IPO), and follow-on equity financings.”
FILING10-K0001193125-26-071593cik 0001653087disclosed by ALEC
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410disclosed by CAI
“Botox Therapeutic is marketed by GSK in Japan.”
FILING10-K0001551152-26-000008cik 0001551152
“In April 2016, the Company entered into the AbbVie Collaboration Agreement to develop and commercialize ARGX-115 (ABBV-151).”
FILING20-F0001697862-26-000032cik 0001697862disclosed by ARGX
“In February 2021, we entered into the AbbVie Development Agreement with Allergan, an AbbVie company, pursuant to which dermal and soft tissue filler products are being developed by AbbVie for commercialization in the medical aesthetics market, using our rhCollagen technology in combination with AbbVie's technology.”
FILING20-F0001213900-26-034393cik 0001631487disclosed by CLGN
“In the United States, we would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of 60% for AbbVie and 40% for us.”
FILING10-K0001193125-26-083012cik 0001341235disclosed by ALDX
Watchlist prices, news filtered to it, and its next report on your desk.
ABBV (AbbVie Inc.) has 10 disclosed suppliers and 10 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
High 263.89 at 2:15 pm ET, low 261.67 at 11:15 am ET.
AbbVie Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
AbbVie Inc. has 10 disclosed suppliers and 10 disclosed customers, each named in an SEC filing with the sentence that discloses it.